Latest Breaking News On - Ltimovacs rebounds on new universal cancer vaccine data for mesothelioma - Page 1 : vimarsana.com

After failing its primary endpoint of progression-free survival, new data shows UV1 plus Bristol Myers Squibb’s Opdivo and Yervoy reduces risk of death by 27% over the checkpoint inhibitors alone.

Bristol myers squibb opdivoBristol myers squibbOrphan drug designationFast track designationLtimovacs rebounds on new universal cancer vaccine data for mesothelioma